JP2014505010A5 - - Google Patents

Download PDF

Info

Publication number
JP2014505010A5
JP2014505010A5 JP2013529343A JP2013529343A JP2014505010A5 JP 2014505010 A5 JP2014505010 A5 JP 2014505010A5 JP 2013529343 A JP2013529343 A JP 2013529343A JP 2013529343 A JP2013529343 A JP 2013529343A JP 2014505010 A5 JP2014505010 A5 JP 2014505010A5
Authority
JP
Japan
Prior art keywords
isolated peptide
domain
peptide
mutated
kis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013529343A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014505010A (ja
JP6383151B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/051827 external-priority patent/WO2012037397A2/en
Publication of JP2014505010A publication Critical patent/JP2014505010A/ja
Publication of JP2014505010A5 publication Critical patent/JP2014505010A5/ja
Application granted granted Critical
Publication of JP6383151B2 publication Critical patent/JP6383151B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013529343A 2010-09-15 2011-09-15 脳損傷治療用ｓｔｅｐ誘導ペプチド Expired - Fee Related JP6383151B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38320810P 2010-09-15 2010-09-15
US61/383,208 2010-09-15
PCT/US2011/051827 WO2012037397A2 (en) 2010-09-15 2011-09-15 Step-derived peptide for brain injury treatment

Publications (3)

Publication Number Publication Date
JP2014505010A JP2014505010A (ja) 2014-02-27
JP2014505010A5 true JP2014505010A5 (enExample) 2014-10-16
JP6383151B2 JP6383151B2 (ja) 2018-08-29

Family

ID=45832252

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013529343A Expired - Fee Related JP6383151B2 (ja) 2010-09-15 2011-09-15 脳損傷治療用ｓｔｅｐ誘導ペプチド

Country Status (5)

Country Link
US (3) US9068172B2 (enExample)
EP (1) EP2616485A4 (enExample)
JP (1) JP6383151B2 (enExample)
CA (1) CA2811086C (enExample)
WO (1) WO2012037397A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2616485A4 (en) * 2010-09-15 2014-04-02 Stc Unm STEPPED DEVELOPED PEPTIDE FOR THE TREATMENT OF BRAIN INJURIES
GB201314610D0 (en) 2013-08-15 2013-10-02 Blueberry Therapeutics Ltd Compounds and their uses
WO2021155354A1 (en) * 2020-01-31 2021-08-05 Unm Rainforest Innovations Regulation of post-ischemic inflammatory response
RO135590A1 (ro) 2020-08-31 2022-03-30 Szedlacsek Ştefan Eugen Peptide de interferenţă ca inhibitori ai interacţiunilor legate de endocitoza receptorilor ampa

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015834A (en) 1992-10-20 2000-01-18 Toronto Neuroprotection Group In vivo treatment of mammalian cells with a cell membrane permeant calcium buffer
CA2494348C (en) 2002-08-01 2014-04-08 Yeda Research And Development Co. Ltd. Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
US20050142630A1 (en) 2003-12-08 2005-06-30 Agy Therapeutics, Inc. Interaction of NMDA receptor with the protein tyrosine phosphatase step in psychotic disorders
AU2007226134A1 (en) 2006-03-16 2007-09-20 Mor Research Applications Ltd. Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
US20090004112A1 (en) 2006-04-21 2009-01-01 The Trustees Of Columbia University In The City Of New York Methods for the treatment of neurodegenerative diseases using nmda receptor glycine site antagonists
KR100999043B1 (ko) * 2007-12-04 2010-12-09 한국생명공학연구원 융합 단백질을 사용하지 않는 인간 단백질 타이로신탈인산화 효소의 활성 도메인 대량 생산 방법
WO2009099563A2 (en) 2008-02-05 2009-08-13 Blanchette Rockefeller Neurosciences Institute Combination of a nmda receptor channel blocker and a pkc activator for treatment of alzheimer's disease
EP2616485A4 (en) * 2010-09-15 2014-04-02 Stc Unm STEPPED DEVELOPED PEPTIDE FOR THE TREATMENT OF BRAIN INJURIES

Similar Documents

Publication Publication Date Title
HRP20190227T1 (hr) Životinje koje nisu ljudi, koje imaju humanizirani gen za protein za reguliranje signala
BR112015004696A2 (pt) polipeptídeos quiméricos tendo especificidade de ligação alvejada
JP2017500061A5 (enExample)
MX2009004147A (es) Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1.
JP2016527891A5 (enExample)
JP2017514496A5 (enExample)
GB201206559D0 (en) Polypeptide
JP2013530689A5 (enExample)
JP2014224126A5 (enExample)
MX382929B (es) Polipéptido heterodimerizado.
PE20220960A1 (es) Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidopteros
MX2016011517A (es) Peptidos de crmp2 no narcoticos que seleccionan como diana canales de sodio para el dolor cronico.
NZ701125A (en) Improved chymosine enzyme variants
NZ629843A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
JP2015533791A5 (enExample)
EP2589658A4 (en) PARTICLE POLYPEPTIDE OF THE REIC / DKK-3 PROTEIN
JP2020513810A5 (enExample)
EA201591609A1 (ru) Варианты альфа-амилазы
JP2011509093A5 (enExample)
IN2014DN09367A (enExample)
EP4306123A3 (en) Saposin-a derived peptides and uses thereof
JP2010265269A5 (enExample)
MY195726A (en) Steviol Glycoside Transport
DOP2017000287A (es) Analogos glp-1 lipidados resistentes a proteasa
JP2016515123A5 (enExample)